Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Universe of Impeccable Pearls: A Manual for Valuable Gems - 2Bahrain cracks down on dissent as war grinds on
- 3Comet MAPS faces a make-or-break moment as it dives toward the sun on April 4 — could it shine in the daytime sky?
- 4SpaceX shatters its rocket launch record yet again — 165 orbital flights in 2025
- 5Avoid Slam: Exploring the Pickup Truck Transformation
- 7 Strange Devices to Make Your Party Stick Out!
- Manual for Famous Beverages 2024
- Oil magnate’s Venezuela detainment spooks industry
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Police break up illegal chicken slaughter in Germany
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- The Best Web-based Courses for Ability Advancement
- Air New Zealand cuts flights and hikes fares as fuel prices surge
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
